Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Italian Stock Exchange  >  Recordati    REC   IT0003828271

RECORDATI

(REC)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Italian Stock Exchange
02/17/2020 02/18/2020 02/19/2020 02/20/2020 02/21/2020 Date
41.1(c) 41.53(c) 42.16(c) 41(c) 40.63(c) Last
323 069 277 309 376 172 395 960 529 909 Volume
+1.86% +1.05% +1.52% -2.75% -0.90% Change
More quotes
Financials (EUR)
Sales 2020 1 583 M
EBIT 2020 505 M
Net income 2020 364 M
Debt 2020 798 M
Yield 2020 2,50%
Sales 2021 1 674 M
EBIT 2021 543 M
Net income 2021 389 M
Debt 2021 808 M
Yield 2021 2,71%
P/E ratio 2020 23,4x
P/E ratio 2021 21,8x
EV / Sales2020 5,74x
EV / Sales2021 5,43x
Capitalization 8 291 M
More Financials
Company
Recordati specializes in the research, development, production and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical and OTC products (84.1%): for the treatment of viral infections, cardiovascular, dermatological, gynecological diseases,... 
Sector
Pharmaceuticals
Calendar
04/30Shareholder meeting
More about the company
Surperformance© ratings of Recordati
Trading Rating : Investor Rating :
More Ratings
Latest news on RECORDATI
02/17RECORDATI : Launch of a share buy-back program to service the stock option plans
PU
02/14RECORDATI : Preliminary 2019 results confirm continued growth of sales and profi..
PU
02/14RECORDATI : 2019 Preliminary FY results - 2020 Targets
PU
02/14RECORDATI : Preliminary 2019 results confirm continued growth of sales and profi..
GL
02/11RECORDATI : annual earnings release
02/04RECORDATI : Change in 2020 corporate events' calendar
PU
01/15RECORDATI : Isturisa® (osilodrostat) approved
GL
2019RECORDATI : Ex-dividend day for interim dividend
FA
2019RECORDATI : Chmp adopts positive opinion for isturisa® (osilodrostat)
GL
2019RECORDATI : Announces growth in the first nine months 2019. revenues +8.6%, ebit..
AQ
2019RECORDATI : Inaugurazione del padiglione giovanni recordati all'ospedale dei bam..
PU
2019RECORDATI : Acquisition of worldwide rights to signifor® and osilodrostat (lci69..
AQ
2019RECORDATI : Il premio internazionale per la ricerca scientifica arrigo recordati..
PU
2019RECORDATI : Arrigo recordati international prize for scientific research awarded..
PU
2019RECORDATI : Public disclosure compliance
PU
More news
News in other languages on RECORDATI
02/11RECORDATI : Veröffentlichung des Jahresergebnisses
02/11RECORDATI : publication des résultats annuels
01/21AVIS D'ANALYSTES DU JOUR : Capgemini, LVMH, Kering, Iliad, Hermès, Fevertree, Vo..
01/21STOCK MARKET PARIS : Trump et Macron font baisser la pression
2019RECORDATI : Ex-dividend day for interim dividend
More news
Analyst Recommendations on RECORDATI
More recommendations
Stock Trading Strategies
RECORDATI - 2019
Hesitation should subside in favor of volatility
BUY
More Stock Trading Analysis
Sector news : Pharmaceuticals - NEC
02/21Marriott Hires Former Merck CIO as Tech Chief
DJ
02/21Pharmaceutical companies develop system to better track counterfeit drugs
RE
02/21DAVIDSON KEMPNER CAPITAL MANAGEMENT : Form 8.3 - Allergan Plc
DJ
02/21ALLERGAN : Form 8.3 -
DJ
02/21ABBVIE : Form 8.3 -
DJ
More sector news : Pharmaceuticals - NEC
Chart RECORDATI
Duration : Period :
Recordati Technical Analysis Chart | REC | IT0003828271 | MarketScreener
Technical analysis trends RECORDATI
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 43,08  €
Last Close Price 40,63  €
Spread / Highest target 20,6%
Spread / Average Target 6,02%
Spread / Lowest Target -6,47%
EPS Revisions
Managers
NameTitle
Andrea Recordati Chief Executive Officer & Director
Luigi Felice La Corte Group Chief Financial Officer
Raffaele Sabia SVP-Pharmaceutical Research & Development
Fritz Squindo Director & Group General Manager
Michaela Castelli Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
RECORDATI9.13%9 006
JOHNSON & JOHNSON1.71%395 024
ROCHE HOLDING AG10.08%300 195
NOVARTIS2.89%218 568
MERCK AND COMPANY-9.47%209 636
PFIZER-8.50%197 679